12 March 2024: Original Paper
Use of LCP-Tacrolimus (LCPT) in Kidney Transplantation: A Delphi Consensus Survey of Expert Clinicians
Alexander Wiseman 1ADEF* , Tarek Alhamad 2DE , Rita R. Alloway 3DEF , Beatrice P. Concepcion 4DE , Matthew Cooper 5DE , Richard Formica 6DE , Christina L. Klein 7DE , Vineeta Kumar 8DEF , Nicolae Leca 9DE , Fuad Shihab 10DE , David J. Taber 11DE , Sarah Mulnick 12ABCDE , Donald M. Bushnell 12BCDE , Monica Hadi 13ABCDE , Suphamai Bunnapradist 14ADEFDOI: 10.12659/AOT.943498
Ann Transplant 2024; 29:e943498
Table 2 Quality of published evidence: adverse effects with LCPT.
| Panelist | |||||
|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 |
| Low | Moderate | High | Moderate | High | Low |
| Very low | Low | Low | Very low | Low | Low |
| Low | Moderate | Low | Low | Moderate | Moderate |
| Very low | Low | Low | Low | Low | Low |
| High | Moderate | High | Moderate | Moderate | Low |
| Moderate | Low | Moderate | Low | Low | Moderate |
| Moderate | Low | Moderate | Low | Low | Low |
| Moderate | Low | Low | Low | Very low | Low |
| DGF – delayed graft function; N/A – not applicable; NODAT – new-onset diabetes after transplantation; QOL – quality of life. | |||||